The company's lead product candidate, AO-176, is currently in Phase 1/2 clinical trials for the treatment of select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies. Their next-generation anti-CD47 antibodies are highly differentiated and have the potential to improve upon the safety and efficacy profile relative to other agents in this class. These antibodies not only act as immune checkpoint inhibitors but also selectively kill tumor cells, helping patients with required treatment options to treat cancer. AO-176 works by blocking the “don’t eat me” signal for macrophages, but also has additional mechanisms including directly killing tumor cells and inducing Immunogenic Cell Death. The company's headquarters is in Brisbane, CA, and their scientific research laboratory is in St. Louis, MO.